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Abstract. Alzheimer’s disease (AD) clinical trials, focused on disease modifying drugs and conducted in patients with mild
to moderate AD, as well as prodromal (early) AD, have failed to reach efficacy endpoints in improving cognitive function in
most cases to date or have been terminated due to adverse events. Drugs that have reached clinical stage were reviewed using
web resources (such as clinicaltrials.gov, alzforum.org, company press releases, and peer reviewed literature) to identify late
stage (Phase II and Phase III) efficacy clinical trials and summarize reasons for their failure. For each drug, only the latest
clinical trials and ongoing trials that aimed at improving cognitive function were included in the analysis. Here we highlight
the potential reasons that have hindered clinical success, including clinical trial design and choice of outcome measures,
heterogeneity of patient populations, difficulties in diagnosing and staging the disease, drug design, mechanism of action,
and toxicity related to the long-term use. We review and suggest approaches for AD clinical trial design aimed at improving
our ability to identify novel therapies for this devastating disease.
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BACKGROUND
Treatments to prevent or slow down cognitive
decline in Alzheimer’s disease (AD) remain an
unmet therapeutic need. The drugs that have been
approved to date for treatment of mild-to-moderate
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AD are acetylcholine esterase inhibitors, including
tacrine (first approved treatment, withdrawn soon
after because of reports of liver toxicity), donepezil
(also approved for severe AD), rivastigmine (also
approved for severe AD), and galantamine [1, 2].
These drugs increase levels of available acetyl-
choline, associated with memory and learning, during
synaptic transmission and thus compensate for the
diminished function of cholinergic neurons. Though
the established mechanism is symptomatic, Dubois
et al. recently reported a reasonably powered mul-
ticenter trial of donepezil versus placebo in mild
cognitive impairment (MCI) that demonstrated sig-
nificant effect of the drug in preserving hippocampal
and whole brain volume at one year versus placebo
[3]. In addition, memantine, an uncompetitive (open-
channel) N-methyl-D-aspartate (NMDA) antagonist
with neuroprotective properties [4], is approved for
treatment of moderate to severe AD.
Numerous clinical trials have explored agents that
could potentially not only interfere with the phys-
iology of the disease but also provide short-term
symptomatic improvement. However, to date none of
the AD modifying treatments has reached regulatory
approval.
While the mechanism of the onset of AD is still
not fully understood, it is recognized that a strong
genetic risk component is usually involved [5–11].
In addition to subjects’ genetic make up, multiple
other lifestyle factors including physical and men-
tal exercise, heart disease, diabetes, lower education,
and mental diseases are thought to accelerate AD
progression [12, 13].
Two primary neuropathologies in the brains of
AD patients have been recognized and studied exten-
sively over the last two decades, including amyloid
plaques formation comprising aggregated amyloid-
 (A) and neurofibrillary tangles (NFTs) formed
by aggregation of hyperphosphorylated tau pro-
tein. The aggregation and extracellular deposition
of A oligomers, drives neuronal death and AD
pathogenesis [14, 15]. While pathologic concen-
trations of A (nanomolar and micromolar) are
considered neurotoxic, soluble A protein present in
low (picomolar) concentrations in normal brains, is
thought to have multiple functions including modu-
lating synaptic activity, memory formation, neuronal
survival, antioxidant activity, effects on Ca trans-
port, and maintenance of blood-brain barrier (BBB)
integrity [16]. The sequential cleavage of native trans-
membrane amyloid- protein precursor (APP),
thought to have a role in neurodevelopment, synap-
togenesis, cell adhesion, and memory formation
[17–20], is known to be the critical step in formation
of A peptides. It is believed that accumulation of A
oligomers hampers synaptic transmission and causes
irreversible AD progression through an imbalance in
production and clearance in neuronal synapses [21].
Several approaches to AD treatment have been
tested in clinical trials, including agonists and antag-
onists of neurotransmitter receptors, -secretase
(-site APP cleaving enzyme - BACE) or -
secretase inhibitors, therapies targeting A clearance,
prevention of A aggregation, modulation of
phosphorylation and clearance of tau protein, as
well as anti-inflammation compounds and multiple
immunotherapy agents directed against A and tau
(Fig. 1). Among those, the BACE inhibitors, thought
to improve cognitive and functional performance by
suppressing A production, are the widely chosen
targets.
However, A deposits in the brain start to accu-
mulate years before cognitive symptoms appear [22].
While prevailing opinion supported by the stronger
association of A with genetic predisposition is that
deposition of A drives the pathology of the disease,
NFTs are more closely associated with the cognitive
decline [23, 24]. While transient and reversible hyper-
phosphorylation of tau has been reported to occur
in normal brains during fetal development, anesthe-
sia, and hypothermia, it is believed that in AD, the
irreversible hyperphosphorylation of tau leads to neu-
ronal loss and consequently to cognitive impairment
[25].
Recent studies with a three-dimensional (3D) in
vitro model of AD showed that APP and PSEN1 gene
mutations induce extracellular deposition of A, and
plaque formation, as well as tau pathology [26]. Fur-
ther, these studies suggest that phosphorylated tau
(p-tau) accumulations are induced by A accumula-
tion. Other studies of A and tau pathology in the
course of AD in human samples showed that solu-
ble A oligomers were abundantly present in early
stages of AD, while p-tau did not increase until late
stages of the disease [27]. Tau imaging studies using
18F T807 PET in patients with MCI and AD demen-
tia, reported high levels of tau in neocortex correlate
with high A burden [28]. It has been reported that
NFTs may form independently of A burden due to
other neural death pathways [25, 29].
Therapeutic strategies postulate that preventing tau
hyperphosphorylation and aggregation can decrease
formation of NFTs. Research has identified sev-
eral potential therapeutic approaches: modulation of
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Fig. 1. Schematic Representation of Therapeutic Strategies. 1) Enhancement of neurotransmission; 2) Reduction of A production and
aggregation; 3) Enhancement of A clearance; 4) Prevention of tau aggregation; 5) Anti-inflammatory agents; 6) Enhancement of microglial
phagocytosis.
tau phosphorylation, prevention of tau aggregation,
and promotion of tau clearance by intracellular and
extracellular proteolysis and phagocytosis, as well as
anti-tau directed immunotherapies [30, 31]. Only a
few drugs that target tau phosphorylation and aggre-
gation have reached late stage clinical trials. In part,
this may be due to differences in structure, confor-
mation, and complexity of changes during AD of
tau protein compared to A (Table 1). While A
consists of 36–42 amino acids, the human central
nervous system expresses six tau isoforms that com-
prise from 352 to 441 amino acids with four sequence
repeats in normal as compared to three sequence
repeats in AD [32, 33]. Further, changes in A and
tau during the progression of AD are very different.
Extracellular A modifications during AD progres-
sion involve slow polymerization into oligomers that
further aggregate. Initial tau modifications in AD
progression are intracellular. Therefore, targeting tau
protein as the therapeutic approach poses more com-
plex challenges than targeting A.
Inflammation triggered by innate immunity has
also been reported to play an important role during
both the early and late stages of the disease and con-
tribution of glia to AD pathology and Ametabolism
has been widely studied [34–38]. Microglia are impli-
cated in propagation of hyperphosphorylated tau
between neurons via exosomes [39]. In addition to
pro-inflammatory response, microglial activation to
phagocytic states is believed to have neuroprotective
properties [37, 38]. Katsel et al. showed using genetic
and protein expression studies that development and
progression of dementia depend on the age at onset
and are different in demented younger and old aging
populations; these features highlight the importance
of the immune system in preventing cognitive decline
[40].
Therefore, it is hypothesized that neuroinflamma-
tion plays a major role in AD progression and that
activation and modulation of the innate immune sys-
tem may lead to new approaches to treatment and
prevention of cognitive decline in progression of AD.
While a number of anti-inflammatory drugs have
been tested in therapeutic controlled clinical trials,
none have been shown to slow the progression of
cognitive symptoms in patients with mild to moder-
ate AD [41–50]. For example, early epidemiological
studies of NSAIDs, such as ibuprofen, reported lower
rates of AD among individuals who had been tak-
ing these drugs for chronic treatment of inflammatory
conditions [51, 52]. However, controlled clinical tri-
als of ibuprofen at a dose of 400 mg/day showed no
cognitive improvement and had known side effects
[53].
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Table 1
Comparison of properties of Tau and A proteins
Tau A
Structure
Role Tabular stabilizer Signal transduction /other
Size (MW) 55,000–62,000 A42 = 45
# amino acids 352–441 36–43
Normal structures Six isoforms, 4 sequence repeats Soluble/single
Slow polymerization
Normal washout
Structures in AD 3 sequence repeats Oligomers and tangles
Phosphorylation & tangles
AD tangles Intra neuron Synapse/interneuron
Clinical trials that targeted A plaque clearance in
mild to moderate AD were potentially doomed to fail
because at the onset of cognitive symptoms the brain
has already been compromised with massive neuronal
death. There is a general agreement that A plaque
removal cannot compensate for neural dysfunction
and death. For mild to moderate AD, stabilizing
AD progression by slowing down or inhibiting its
pathology is the only viable treatment option. Novel
approaches to treat AD at the prodromal stage, before
significant neural damage has occurred, attempting to
slow down and prevent disease progression are being
explored.
Other pathogenic mechanisms have been reported
to be associated with the progression of AD [54, 55],
and these potential treatments have been studied in
animal models and clinical trials. These approaches
include antioxidants, drugs that target oxidative stress
damage and mitochondrial dysfunction, iron deregu-
lation, and abnormal cholesterol metabolism.
Given the complexity of AD progression and asso-
ciated immune response, new approaches targeting
multiple AD pathologies are being studied. Further,
new understanding of the multiple roles of microglia
and factors that affect their function in the progres-
sion of AD [10, 11, 35, 56, 57], has potential to open
vastly new therapeutic options and targets.
SYMPTOMATIC AND DISEASE
MODIFYING APPROACHES: CLINICAL
EXPERIENCE
The drugs currently used to treat cognitive
decline (i.e., cholinesterase inhibitors, NMDA recep-
tor antagonist), and drugs that treat behavioral and
psychological symptoms (such as antidepressants
and antipsychotic drugs, despite the controversies
surrounding their use) have limited therapeutic value.
However, despite the large number of approaches
tested in clinical trials, cholinesterase inhibitor and
NMDA receptor antagonist remain the only approved
treatments for AD. Several reviews already provide
comprehensive summaries of ongoing clinical and
pre-clinical efforts to treatment of AD [54, 55, 58,
59]. Here, we focus on reviewing late stage clinical
trials that did not reach efficacy endpoints and ongo-
ing clinical trials, highlighting possible reasons for
failures based on the information that has emerged
from the body of clinical research.
As we noted earlier all approaches to treat AD
targeted one mechanism of action associated with dis-
ease pathology and, further, the majority of research
of validation of new targets evolved around A.
Expanding treatment options to combination ther-
apy addressing several mechanisms is an important
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direction with potential to impact treatment as has
been shown to be successful for other complex
diseases (e.g., HIV and cancer treatment). This multi-
faceted approach is even more reasonable given the
complex aging brain, where immune surveillance and
increased vulnerability to inflammatory response can
accelerate disease progression. Recently, Eli Lilly
started a Phase II study of LY3202626, a small
molecule BACE inhibitor, administered together with
monoclonal antibody LY3002813 targeting A(p3-
42), a pyroglutamate form of A localized to aggre-
gated A in amyloid plaques. However, the combina-
tion arm in this trial was halted due to concerns about
impact of the BACE inhibition on general cognition.
Other largely unsuccessful attempts to improve
cognitive decline by enhancing neurotransmission
are shown in Table 2 [60–71]. Despite encouraging
preclinical and Phase II clinical results, the num-
ber of agents thought to improve cognitive decline
by enhancing cholinergic neurotransmission, using
serotonin 6 (5-HT6) receptor antagonists, Intepir-
dine [60], Idalopirdine [61], and PF-05212377 [62],
failed to reach efficacy endpoints. Similarly, previ-
ous attempts to enhance acetylcholine response using
H3 receptor antagonists, ABT-288, GSK239512,
and S 38093, did not show sufficient cognitive
improvement [64–66]. Other clinical trials discon-
tinued due to the lack of efficacy include Xaliproden
(5HT1-A receptor antagonist) [63], Atomoxetine
(norepinephrine uptake inhibitor approved for treat-
ment of ADHD) [68], Dimebon (anti-histamine) [69],
S47445 (agonist of AMPA receptors for glutamate)
[70], and Sembragiline [71]. Encenicline (7nAChR
agonist) Phase III trial was discontinued after adverse
events were noted [67].
The majority of drugs in development are focused
on A hypothesis, attempting to improve cognitive
function through modulation of A and tau lev-
els. (Table 3) [72–87]. The -secretase inhibitors,
i.e., Avagacestat and Semagacestat, as well as some
BACE inhibitors (i.e., Atabecestat) induced serious
side effects [73, 77, 79]. Development of other BACE
inhibitors, such as Lanabecestat and Verubecestat,
has been suspended due to lack of efficacy [74, 76].
Several passive immunotherapy drugs are under-
going clinical testing with mixed results. Bap-
ineuzumab development was terminated because of
the lack of efficacy and risk of adverse effects includ-
ing microhemorrhages in the brain [82]. Intravenous
immunoglobulin (IVIg) showed significant reduc-
tions in plasma A42 levels compared with placebo
but no benefits for improving cognition in patients
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with mild-to-moderate AD dementia, according to
the results of a Phase III trial [46].
Tau-targeting approaches to date have been sparse
(Table 3). LMTM (Methylene Blue, Tau aggregation
inhibitor) was tested in a Phase III study in patients
with mild to moderate AD, and failed to show clinical
improvement [87]. Similarly, late stage clinical trials,
aiming to treat inflammation related to AD including
a number of NSAIDs have also had poor efficacy
results (Table 4).
The ongoing trials generally target earlier stages
of the disease and use in part available biomarkers.
BI 425809, a glycine transporter inhibitor thought
to modulate NMDA receptor function, is currently
in Phase II clinical trial in early AD patients. The
next generation of small molecule BACE inhibitors
(CNP520, Elenbecestat) are still in ongoing clinical
trials in early AD patients and asymptomatic patients.
Elenbecestat is being evaluated in a Phase III study in
early AD patients with confirmed brain amyloid using
positron emission tomography (PET) and/or cere-
brospinal fluid (CSF) assessment. CNP520 is being
tested in subjects who are otherwise healthy but at
increased risk of developing AD based on their age,
genotype, and amyloid levels.
Several passive immunotherapies advanced to
Phase III and prevention trials after mixed Phase II
efficacy results in mild to moderate AD. Crenezumab
Phase III trials in patients with MCI or prodromal AD
with PET and CSF evidence of A pathology using
higher dose, were terminated due to lack of efficacy
[83]. Solanezumab missed on the primary endpoint in
a Phase III trials in patients with mild AD and prodro-
mal AD [85, 86]. It is also tested in the A4 prevention
trial in asymptomatic or mildly symptomatic patients
at risk of developing AD-related cognitive impair-
ment, with amyloid plaque buildup as evidenced by
florbetapir PET scan, with the goal of slowing down
cognitive and memory decline and AD progression.
The trial uses Preclinical Alzheimer Cognitive Com-
posite (PACC) as a primary outcome measure as well
as number of cognitive and functional scales, imaging
and CSF biomarkers as secondary outcome measures.
The results of the A4 prevention trial have not been
reported to date. Gantenerumab is also being inves-
tigated in a Phase II/III trial aimed at preventing
dementia in subjects with an inherited autosomal-
dominant mutation in APP, PSEN1, or PSEN2 [84].
Aducanumab, a human IgG1 monoclonal antibody
targeting aggregated A, failed Phase III trials in
patients with MCI and mild AD confirmed by a pos-
itive amyloid PET scan [80].
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Recently, positive results of the Phase II test-
ing of BAN2401 have been reported at 18 months
despite the fact that the results of interim analy-
sis at 12 months missed the primary endpoint [81].
The Phase II trial results reported statistically sig-
nificant slowing of the course of AD symptoms,
as measured by a combination of cognitive assess-
ments and dementia ratings (ADCOMS). However,
the changes in the Clinical Dementia Rating Sum of
Boxes (CDR-SB) were not statistically significant.
Results were further compounded by exclusion of
APOE4 patients form the highest dose group party
way through the trial. The concern of the differences
between the treatment and control groups remains.
In addition, while the safety profile was reported to
be acceptable (incidence of amyloid-related edema
lower than 10% at any dose, and under 15% in patients
with APOE4 taking the highest dose), the concern
of effects of chronic administration remain and the
reported results warrant periodical repeated moni-
toring of patients making disease management even
more complex.
Active immunotherapy trials include CAD106,
vaccine that induces immunity to A without elic-
iting an inflammatory response, currently in a Phase
II/III prevention trial in homozygous APOE4 sub-
jects who are cognitively normal. Tau targeting
approaches through passive (BIIB092, C2N 8E12,
LY3303560, RO7105705) and active (AADvac-1,
ACI-24) immunotherapy are currently in Phase II
clinical trials.
Few anti-inflammatory agents remain in clinical
testing: Pioglitazone, an insulin sensitizer that is
approved for treatment of Type 2 diabetes mellitus,
GRF6019 (young adult plasma), and Neflamapimod,
which is a small molecule believed to shift microglial
pro-inflammatory state to a phagocytic state.
AZTherapies reported research results of bene-
ficial effects of a combination treatment, currently
in Phase III clinical testing, that studies modified
cromolyn sodium, an asthma therapeutic agent, in
combination with newly formulated low dose ibupro-
fen. It was shown that the combination treatment may
simultaneously affect A aggregation and inflamma-
tion associated with AD in animal models of the
disease [88–90].
DISCUSSION
A large number of AD clinical trials have failed
despite significant advances in scientific understand-
ing of the disease. The fact that over 400 trials
testing over 200 therapeutics have been performed
to date with a 99.6% failure rate (i.e., a success
rate of only 0.4%) clearly illustrates the importance
of the issue [2, 91]. In Tables 2–4, we highlight
the late stage clinical trials, some of which are still
ongoing, using various disease modifying and symp-
tomatic approaches. An overview of recent clinical
trial reports indicates that potential flaws include
overall clinical trial design with utilized statistical
measures that are perhaps not aligned with the stud-
ies’ objectives, heterogeneity of patient populations
due to deficient inclusion criteria, and difficulties
in diagnosing early disease for both treatment and
placebo groups. Other flaws include single target
mechanism, drug bioavailability, genetic making, and
toxicity from chronic administration, which alone or
in combination may have contributed to recent fail-
ures. These potential shortcomings are explored in
detail below.
Study design
Most studies to date were performed in mild and
moderate AD patients, with neuronal damage already
present to a considerable extent. At this stage, the
disease progression path and rate are uncertain and
show individual variability in part due to variabil-
ity in dementia rating and patient populations [92,
93]. In mild and moderate AD patient populations,
it becomes apparent that the use of amyloid and
tau modulation agents to inhibit generation and/or
increase clearance may not compensate for the neu-
ronal damage that is already present, thus challenging
the clinical trial’s odds of success. Some published
results show no or very slow cognitive decline in their
placebo group, strongly suggesting a failure in clin-
ical trial design [2]. Other trials have suffered from
lack of sensitivity of standard measures of cognitive
performance (i.e., CDR-SB) at early and prodromal
stages of the disease [93, 94].
In addition, the widely used CDR-SB scale, while
clinically meaningful, was not designed to be used
in traditional statistical analysis of efficacy of treat-
ment. Because the evaluation is subjective, additional
variability may be introduced in multicenter trials,
further hampering success. When used as a measure
of disease progression in the evaluation of the primary
endpoints, unequal size of the change between stabi-
lization and/or improvement in the treatment group
(a small change of a few points in this population)
as compared to disease progression in the placebo
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group (a larger change). Since the typical annual
change in CDR-SB reported for early AD patients
is between 1-2 points [95, 96], the changes are small
and require large number of subjects to reach sta-
tistical significance, even in cases when the drug is
clinically effective in stabilizing cognitive decline.
As mentioned previously, to overcome the issues
with measuring cognitive change early in AD pro-
gression, Phase II a clinical trial of BAN2401 used
the combination measures, ADCOMS, which at 18
months showed statistically significant changes com-
pared to placebo. However, the changes in CDR-SB
were not statistically significant, which could be, in
part, attributed to the selected patient population and
disease staging in the trial. In prevention trials, the
time to diagnosis of dementia has been used as an
endpoint and it is likely to show similar large variabil-
ity. Further, multiple trials have attempted to conduct
subgroup analysis after failures to report a clinical
benefit. These attempts have been criticized to pro-
vide inaccurate information as subgroups are often
not properly randomized and do not have significant
sample size [91].
Patient population
The majority of clinical trials conducted to date
included patients aged from 50 to 90 years old,
leading to large variability in the cognitive impair-
ment and disease progression. Thus, heterogeneous
mild to moderate AD patient populations require a
large number of subjects to accommodate for age,
gender, disease stage, genetic predisposition, demen-
tia type (such as Lewy body, senile and vascular,
alcohol abuse, injury, or a result of other diseases)
and inevitably lead to obscuring observed treatment
effects and to failure to show clinical efficacy. The
need to identify homogeneous patient populations at
risk of developing AD brain pathology requires the
use of imaging, CSF, and blood for disease staging,
in addition to cognition and functional measures.
Bioavailability and toxicity from chronic
administration
It has been noted previously that many drugs in
development suffer from inadequate brain bioavail-
ability and appropriate dose selection to show clinical
benefit due to toxicity from chronic administration
[91]. This is true for small molecules that may be
transported from the central nervous system, even
after crossing the BBB to target enzyme inhibi-
tion or a biochemical pathway, and it is particularly
important for large molecules, such as monoclonal
antibodies and other biologic drugs. Data on clin-
ical trials that failed due to toxicity issues are
shown in Table 4 (drugs targeting inflammation) and
Table 5 (drugs targeting A [73, 77, 79, 97–102]) and
illustrate the problem in development of disease mod-
ifying treatments. While the clinical development of
most of these drugs was halted before reaching Phase
III, some drugs (such as Bapineuzumab, Azeliragon,
Verubecestat) advanced into Phase III with doses
that were not sufficient to show benefit in cogni-
tive function. The Atabecestat Phase II/III trial was
recently discontinued due to issues with liver toxic-
ity. Similarly, a number of anti-inflammatory agents
(Table 4) failed due to increased risk of adverse events
with chronic administration. The need to adminis-
ter the treatment frequently for several years, with
high risk of systemic toxicity, requires that an ade-
quate dose is selected early in the drug development
phase [91].
Table 5
Discontinued clinical trails targeting A: Adverse events and toxicity
Drug Description/Target Results
AAB-003 A ARIA and microhemorrhages [97]
AN-1792 A Brain inflammation [98]
Atabecestat BACE inhibitor Elevated liver enzymes [73]
Avagacestat -secretase inhibitor Gastrointestinal and dermatological side effects;
Nonmelanoma skin cancers reported; ARIA [77]
Azeliragon RAGE inhibitor High dose was associated with confusion, falls, and
greater ADAS-cog decline; Low dose was not
effective in subsequent trials [99]
LY2886721 BACE inhibitor Abnormal liver biochemistry values [100]
Semagacestat -secretase inhibitor Increased risk of skin cancer and infections [79]
Bexarotene Retinoid (A) Increased blood lipid levels, risk of cardiovascular
side effects [101]
Bapineuzumab A clearance Reversible vasogenic edema APOE 4 carriers [102]
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Intervention is too late for disease modifying
agents
Consistent with the observation that A deposits
in the brain start to accumulate years before cog-
nitive symptoms appear [22], the clinical results
from trials in mild to moderate AD patients, which
attempt to modulate A production and clearance,
indicate that removing plaques will not reverse the
neuronal damage or stop the AD. This limits the
treatment targeting A production and clearance
to be effective only at early stages of the dis-
ease. Limiting A production and aggregation may
have limited benefit in mild to moderate AD. Simi-
larly, stage-dependent efficacy of anti-inflammatory
agents, suggests that these treatments may be use-
ful early in AD [90, 103]. It is hypothesized, that
once A-induced inflammation initiates tauopathy,
neurodegeneration progresses and leads to cognitive
decline.
Biomarkers
The need to focus interventions on a homoge-
neous patient population at an appropriate disease
stage, as well as the need to diagnose the dis-
ease before cognitive symptoms occur, has led to a
renewed focus on identifying and validating biomark-
ers, including structural MRI signs of hippocampal
and global brain atrophy, CSF, and blood analysis
biomarkers as well as the usage of PET imaging
agents. The ability to diagnose the disease at earlier
stages while preserving normal brain function would
significantly contribute to the potential to develop
disease-modifying therapies. So far, no biomarker
proposed for early diagnosis and monitoring treat-
ments has been validated.
Currently, the most widely used CSF biomarkers,
obtained through lumbar puncture, include those tar-
geting amyloid- (A42 or A42/A40), total tau
protein (T-tau) and phosphorylated tau (P-tau181)
[104]. It has been shown that CSF A42 is an indi-
cator of early stages of the disease, while CSF tau
indicates the extent of cognitive decline at later stages
[23, 24]. CSF and blood levels of neurofilament light
chain protein have been shown to correlate well with
neurodegeneration.
The use of CSF biomarkers in research and clini-
cal trials, in addition to clinical criteria is detailed in
the revised diagnostic criteria of AD [24, 105], sug-
gesting the use of CSF biomarkers in differentiating
between AD and other types of dementia. The util-
ity of neuro-inflammatory biomarkers collected from
blood, may have limited use when patients are suffer-
ing from additional systemic inflammation. Burchell
and Panegyres reviewed several other biomarkers and
assays including those involving BBB integrity, mito-
chondrial DNA, vascular endothelial growth factor,
as well as immunological factors involved in AD
pathogenesis [106]. However, these are still in early
development and have not been validated.
With the renewed interest in targeting multiple
disease hallmarks, inclusion of other exploratory
biomarkers in clinical trials may be a critical com-
ponent of advancing the understanding of the role of
neuroinflammation in AD and developing additional
tools for early diagnosis and follow up of disease
progression. The correlation of multiple indicators
with disease progression, that may help to design
improved patient selection related to brain patho-
physiology in the future.
Several imaging techniques, including structural
magnetic resonance imaging (MRI) and 18F-
fluorodeoxyglucose (FDG) are commonly used in
clinical research to assist in early diagnosis. There
has been significant development in the PET imaging
tracers binding to A with the approval of Amyvid
(18F-florbetapir), Vizamyl (18F-flutametamol), and
Neuraceq (18F-florbetaben).
Similarly, recent results suggest that buildup of
tau pathology could better predict future cogni-
tive impairment than A, and subsequently driving
research toward new tau imaging agents. For exam-
ple, increased flortaucipir binding has been shown
to correlate with increased cognitive impairment in
patients with A plaque [107]. Other tau imaging
tracers, including 18F- PI-2620 are currently in clin-
ical testing.
While early clinical trials rarely used imaging and
CSF biomarkers, recent clinical work includes more
frequent use of PET imaging and CSF biomark-
ers, either as a secondary outcome measure and/or
as inclusion criteria. However, in most of these
studies, biomarkers are used in sub-studies with a
much smaller number of subjects (i.e., clinical tri-
als for Verubecestat, Lanabecestat, Bapineuzumab,
Gantenerumab, and Semagacestat).
Genetic testing is particularly useful in identify-
ing individuals at risk of developing AD and has
gained momentum with the number of prevention tri-
als. Some of the genetic testing targets genes with
rare variations that cause inherited AD or those that
are associated with increased risk of developing AD,
such as APOE 4.
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New biomarkers and imaging agents as well as
potentially combinations of biomarkers, that target
specific AD pathology in asymptomatic patients at
risk of developing AD, could potentially assist in
identifying homogeneous patient populations and
provide additional tools for monitoring efficacy of
clinical trials.
Combination treatments
Experience to date points to the fact that AD is
multi-target disease, and that approaches using one
drug, focused on one target may not be sufficient to
achieve improvement of clinical symptoms [55].
Azeliragon, a small-molecule RAGE inhibitor, has
been thought to provide a combined treatment by
lowering A plaque deposition and inducing anti-
inflammatory response, but it failed to reach efficacy
endpoints in Phase III [41]. Other treatments pro-
posed to mediate amyloid beta clearance and provide
anti-inflammatory properties either failed later stage
testing due to poor efficacy (e.g., GM-CSF Leukine,
Intravenous immunoglobulin) or are still in ongo-
ing clinical trials (e.g., Pioglitazone, GC 021109,
GRF6019).
Other approaches targeting both A accumulation
and inflammation associated with AD may be needed
to slow disease progression before symptoms occur.
CONCLUSIONS AND
RECOMMENDATIONS
The number of clinical trials focused on early, mild,
and moderate AD that did not achieve primary end-
points and failed to achieve cognitive improvement
keeps growing. We believe that the scientific ratio-
nale behind all potential AD therapies tested is valid
and supported by in vitro and in vivo animal model
data and that this is not the main reason for these
clinical trial failures. Trial design and analytical out-
come measures are becoming especially important
when attempting to treat a chronically progressive
disease as AD. Brain neurons and synapses expand
the brain network in early years and with aging, net-
work remodeling shifts toward deterioration. This
life-long process is associated with genetic predis-
position, education, lifestyle, and the environment. It
is unequivocally important that new potential ther-
apies address the unique irreversible nature of the
brain aging process. Unlike treatments of other dis-
eases such as cancer, where short term aggressive
treatments are used in doses that induce systemic tox-
icity, destroy normal cells, and/or impact the immune
system, treatment of AD requires approaches that
preserve the balance of A and tau proteins that is
essential for neuronal function and further stabilize
the brain’s innate immune system.
To address multiple parameters affecting complex
AD clinical trial design, we highlight some recom-
mendations and potential new approaches.
Experience to date shows that clinical trial design
and outcome measures have to be adjusted to
allow monitoring of disease progression in the pre-
symptomatic stage of AD with sufficient minimum
clinically important differences. To eliminate other
factors that were associated with failure, clinical
trials should include in the study design adequate
outcome measures and endpoint selections (see
Early Alzheimer’s Disease: Developing Drugs for
Treatment-Guidance for Industry). The challenge
remains to devise methods to reliably identify patients
with preclinical AD and to ensure that the methods
have predictive value. As the duration, complex-
ity, and cost of clinical trials increase, the clinical
research would benefit from introducing appropriate
interim analyses and adaptive clinical trial designs.
The need to eliminate heterogeneity of patient
population, and especially to identify homogeneous
patient populations at risk of developing AD will
require the use of imaging, CSF, and blood biomark-
ers for disease staging, in addition to cognitive and
functional measures. It will be necessary to mini-
mize variations due to age (i.e., limit the age spread
of the study population to patients between 55 to
70, to avoid younger patients that are far from AD
onset and older patients who show faster AD progres-
sion), define proper cutoffs for cognitive performance
(done in most cases with varying rationale, mainly
based on published data), and limit the use of con-
comitant AD medication that affects brain function
(such as strong antipsychotic drugs) at entry. Lim-
iting the use of approved medications (i.e., for a
period of more than six months or a year) during
the trial, unless the test drug is an adjuvant ther-
apy, should also contribute to smaller variation in
cognitive performance during the trial. In addition,
it will be necessary to reflect underlying AD pathol-
ogy when selecting patient population using validated
CSF and/or blood biomarkers as well as proper imag-
ing techniques with adequate ranges for the targeted
disease stage.
Because the treatment is expected to last many
years, systemic toxicity is an expected outcome with
aggressive therapies at high doses. To address this
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concern, new preclinical methods need to be explored
to adequately evaluate potential in vitro or in vivo
toxicity, not only for small molecules but also for
biologic treatments, where effect of chronic treatment
are typically not easily estimated. In slow progress-
ing AD, the risk of chronic toxicity when using high
doses of drugs does not provide benefit rationale as in
treatment of other diseases (i.e., cancer). The lowest
effective dose needs to be determined and validated
based on brain pathophysiology, to provide treat-
ment at A and tau levels typically present in the
brains of patients with early AD. Prolonged brain
titration with the lowest effective doses, sufficient
to treat small daily A and tau changes (reported at
pico and nano molar levels) should provide measur-
able changes that can affect species production and
clearance as well as treat the associated neuroinflam-
mation. These changes are not easily predictable and
are hard to achieve even with low doses of potentially
effective but highly toxic drugs.
AD is a neurodegenerative aging-related disease
with no known cure, and neuronal damage cannot
be fully reversed even if the mechanisms underlying
disease progression are targeted. As a strategy, the
goal of AD treatment should be slowing down neu-
ral degeneration. Therefore, early treatment options,
before the symptoms of AD occur, appear to be
the most viable current approach. However, early
diagnosis of AD, before cognitive symptoms occur,
is still a challenge, because of the lack of appro-
priate biomarkers and diagnostic criteria for this
pre-symptomatic stage of AD. As the focus of cur-
rent research moves toward prevention trials, the aim
of intervention becomes delaying the symptoms and
slowing down progression of the disease, especially
in subjects who are potentially vulnerable to early
disease onset, due to genetic profile, environmental
conditions associated with lifestyle, and other con-
tributing diseases.
It is clear that new approaches to treatment of AD
will require the identification and validation of new
targets and will need to target multiple mechanisms
of action that may slow disease progression, when
used before clinical symptoms appear (Fig. 1). In
addition, performance of drugs that showed limited
efficacy and failed to achieve statistical significance
when used as a single treatment, may be improved by
exploring their combination with anti-inflammatory
mechanisms of action. As an example, Solanezumab,
an A removal antibody with some degree of suc-
cess in clinical studies, could be combined with low
dose anti-inflammatory agent, a mast cell stabilizer as
part of innate immune system, or with an inhibitor of
amyloid peptide oligomerization and polymerization.
Identifying a suitable pool of asymptomatic
patients and following the rate of progression of
the disease is likely to require the use of multiple
biomarkers in addition to effective cognition and
function measures. Thus, the development and val-
idation of new CSF and blood biomarkers, as well
as highly specific PET agents, becomes critical for
future clinical research. To ensure sufficient brain
bioavailability, brain or CSF drug uptake should be
evaluated in the CSF and blood by labeled molecules
or their close analogs using biodistribution and phar-
macokinetics studies in experimental animals or by
brain imaging in humans. This approach should pro-
vide proof of bioavailability and has potential to
increase success of clinical studies and to reduce the
cost and waste of resources associated with unsuc-
cessful clinical trials.
Proposed selection of homogeneous patient popu-
lation, with narrow age range and with early stages
of the disease, as well as the use of CSF and blood
biomarkers in addition to stricter cognition and func-
tional measures, would likely increase the number of
screening failures resulting in higher recruitment cost
and prolong duration of the trials. To address these
issues, we recommend the use of adaptive and interim
analyses, per FDA guidelines, and additional mea-
sures of clinical utility of the treatment. Cognitive and
functional performance scales (such as CDR-SB), are
fairly acceptable scales recommended by the FDA
(see Early Alzheimer’s Disease: Developing Drugs
for Treatment-Guidance for Industry). While useful
in diagnosis and staging of the disease, they have lim-
ited value as a measure of disease progression. The
CDR-SB scale (as well as other cognition and func-
tion tests) was not designed to be used in traditional
statistical analysis of efficacy of treatment. The eval-
uation of the primary endpoints using CDR-SB mean
change from baseline in early AD may potentially be
challenged by the unequal size of the change between
stabilization and improvement (a small change of a
few points in this population) as compared to dis-
ease progression (a larger change). Due to these
potential challenges, we believe that an exploratory
responder analysis may alleviate the issues and
provide additional information on the efficacy of
clinical trials.
Adding CDR-SB analysis at the end of a study
for determining response to drug treatment (stable
or improvement; responder or non-responder) may
be an additional useful tool as an efficacy measure.
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Adaptive and interim analyses, per FDA guidelines,
as well as, exploring responder analysis in the interim
and final analysis, should be considered. Addition-
ally, validated biomarkers may provide more accurate
correlation with the progression of the disease, espe-
cially when used in combination with cognitive and
functional outcomes.
Advances in understanding the role of the brain’s
innate immune system in the development of AD,
and specifically its genetic regulation, have poten-
tial to open new therapeutic solutions. Experience
to date points out that AD is a multi-target dis-
ease, and that approaches using one drug, focused on
one target may not be sufficient to achieve improve-
ment of clinical symptoms. Combination treatments
with multiple targets may potentially lead to effective
therapies.
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